$BBLG
Bone Biologics Corp

2024 Q4 Form 10-Q Financial Statement

#000149315224046020 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $521.3K
YoY Change 2.21%
% of Gross Profit
Research & Development $429.7K
YoY Change -72.71%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $951.0K
YoY Change -54.3%
Operating Profit -$951.0K
YoY Change -54.3%
Interest Expense $19.99K
YoY Change
% of Operating Profit
Other Income/Expense, Net $10.02K
YoY Change -93.74%
Pretax Income -$941.0K
YoY Change -50.99%
Income Tax
% Of Pretax Income
Net Earnings -$941.0K
YoY Change -50.98%
Net Earnings / Revenue
Basic Earnings Per Share -$2.37
Diluted Earnings Per Share -$2.37
COMMON SHARES
Basic Shares Outstanding 2.464M shares 1.801M shares
Diluted Shares Outstanding 1.753M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.566M
YoY Change -19.86%
Cash & Equivalents $3.325M $3.566M
Short-Term Investments
Other Short-Term Assets $499.4K
YoY Change -3.96%
Inventory
Prepaid Expenses $10.00K $18.43K
Receivables
Other Receivables
Total Short-Term Assets $3.861M $4.066M
YoY Change 3.31% -18.36%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $3.861M $4.066M
Total Long-Term Assets $0.00 $0.00
Total Assets $3.861M $4.066M
YoY Change 3.31% -18.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $190.1K
YoY Change -82.72%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $377.7K $273.4K
YoY Change -54.57% -76.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $377.7K $273.4K
Total Long-Term Liabilities $0.00
Total Liabilities $377.7K $273.4K
YoY Change -54.57% -76.89%
SHAREHOLDERS EQUITY
Retained Earnings -$85.00M -$83.50M
YoY Change 5.07% 5.16%
Common Stock $2.953K $2.096K
YoY Change 453.0% -33.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.484M $3.792M
YoY Change
Total Liabilities & Shareholders Equity $3.861M $4.066M
YoY Change 3.31% -18.3%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$941.0K
YoY Change -50.98%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$572.2K
YoY Change -77.65%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.807M
YoY Change
NET CHANGE
Cash From Operating Activities -572.2K
Cash From Investing Activities
Cash From Financing Activities 1.807M
Net Change In Cash 1.234M
YoY Change -148.22%
FREE CASH FLOW
Cash From Operating Activities -$572.2K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2463534 shares
CY2024Q3 us-gaap Cash
Cash
3566426 usd
CY2024Q3 BBLG Advances On Research And Development Contract Services
AdvancesOnResearchAndDevelopmentContractServices
385742 usd
CY2024Q3 BBLG Prepaid Insurance Current
PrepaidInsuranceCurrent
95220 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
18430 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
4065818 usd
CY2024Q3 us-gaap Assets
Assets
4065818 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
190057 usd
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2096740 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2096740 shares
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
52681 usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2024Q3 BBLG Warrant Liability
WarrantLiability
17629 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
273402 usd
CY2024Q3 us-gaap Liabilities
Liabilities
273402 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
2096 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-83499663 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
3792416 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4065818 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
429747 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1574850 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1025814 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
521274 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
506040 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1638409 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
951021 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2080890 usd
us-gaap Operating Expenses
OperatingExpenses
2664223 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-951021 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2080890 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2664223 usd
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
9974 usd
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-160645 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-38122 usd
CY2024Q3 us-gaap Interest Income Other
InterestIncomeOther
19993 usd
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
536 usd
us-gaap Interest Income Other
InterestIncomeOther
35396 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
161181 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
73518 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-941002 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1919709 usd
us-gaap Net Income Loss
NetIncomeLoss
-2590705 usd
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001419554
CY2023Q4 BBLG Research And Development Contract Liabilities
ResearchAndDevelopmentContractLiabilities
usd
CY2024Q3 BBLG Accrued Legal Settlement
AccruedLegalSettlement
usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2023Q3 us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
usd
us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
usd
CY2023Q1 BBLG Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
usd
CY2023Q2 BBLG Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
usd
BBLG Increase Decrease In Accrued Legal Settlement
IncreaseDecreaseInAccruedLegalSettlement
usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Stock Issued1
StockIssued1
usd
BBLG Deemed Dividend Warrant Inducement
DeemedDividendWarrantInducement
usd
BBLG Extinguishment Of Warrant Liability Upon Exercise Of Warrants
ExtinguishmentOfWarrantLiabilityUponExerciseOfWarrants
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
shares
BBLG Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40899
dei Entity Registrant Name
EntityRegistrantName
Bone Biologics Corporation
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
42-1743430
dei Entity Address Address Line1
EntityAddressAddressLine1
2 Burlington Woods Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Ste 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Burlington
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01803
dei City Area Code
CityAreaCode
(781)
dei Local Phone Number
LocalPhoneNumber
552-4452
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.001
CY2023Q4 us-gaap Cash
Cash
3026569 usd
CY2023Q4 BBLG Advances On Research And Development Contract Services
AdvancesOnResearchAndDevelopmentContractServices
328844 usd
CY2023Q4 BBLG Prepaid Insurance Current
PrepaidInsuranceCurrent
372350 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
3737763 usd
CY2023Q4 us-gaap Assets
Assets
3737763 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
360662 usd
CY2024Q3 BBLG Research And Development Contract Liabilities
ResearchAndDevelopmentContractLiabilities
65716 usd
CY2023Q4 BBLG Accrued Legal Settlement
AccruedLegalSettlement
414989 usd
CY2023Q4 BBLG Warrant Liability
WarrantLiability
55751 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
831402 usd
CY2023Q4 us-gaap Liabilities
Liabilities
831402 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
534238 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
534238 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
534 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
87289983 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
83814785 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80908958 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
2906361 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3737763 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6460747 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1807548 usd
us-gaap Operating Expenses
OperatingExpenses
8268295 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-8268295 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-867930 usd
us-gaap Interest Income Other
InterestIncomeOther
1519 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10019 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
869449 usd
us-gaap Net Income Loss
NetIncomeLoss
-7398846 usd
CY2024Q3 us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
3212504 usd
us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
3212504 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4153506 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1919709 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5803209 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7398846 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1753409 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1753409 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
391854 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
391854 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1196295 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1196295 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
197855 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
197855 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.37
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.37
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.90
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.90
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.85
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-37.40
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-37.40
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
2906361 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
77400 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1504113 usd
CY2024Q1 BBLG Stock Issued During Period Value Exercise Of Prefunded Warrants
StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants
363 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-865970 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
3674948 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
17443 usd
CY2024Q2 BBLG Stock Issued During Period Value Exercise Of Prefunded Warrants
StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants
299 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-783733 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
2908957 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
17941 usd
CY2024Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1806520 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
3212504 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-3212504 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-941002 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
3792416 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
5947308 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
44764 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
490226 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3709899 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2772399 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
16670 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
220798 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4452163 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1769238 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
5692792 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
5692792 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
20026 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1919709 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
3793109 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
3793109 usd
us-gaap Net Income Loss
NetIncomeLoss
-2590705 usd
us-gaap Net Income Loss
NetIncomeLoss
-7398846 usd
us-gaap Share Based Compensation
ShareBasedCompensation
88065 usd
us-gaap Share Based Compensation
ShareBasedCompensation
81460 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-38122 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-867930 usd
BBLG Increase Decrease In Advances On Research And Development Contract Services
IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices
-56898 usd
BBLG Increase Decrease In Advances On Research And Development Contract Services
IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices
170205 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-268700 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-262962 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-93205 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
42859 usd
BBLG Increase Decrease In Research And Development Contract Liabilities
IncreaseDecreaseInResearchAndDevelopmentContractLiabilities
65716 usd
BBLG Increase Decrease In Research And Development Contract Liabilities
IncreaseDecreaseInResearchAndDevelopmentContractLiabilities
171401 usd
BBLG Increase Decrease In Accrued Legal Settlement
IncreaseDecreaseInAccruedLegalSettlement
-414989 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2771438 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7537889 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1504113 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4452163 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
662 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
1806520 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3311295 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4452163 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
539857 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3085726 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3026569 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7538312 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3566426 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4452586 usd
us-gaap Stock Issued1
StockIssued1
77400 usd
BBLG Deemed Dividend Warrant Inducement
DeemedDividendWarrantInducement
3212504 usd
BBLG Extinguishment Of Warrant Liability Upon Exercise Of Warrants
ExtinguishmentOfWarrantLiabilityUponExerciseOfWarrants
711024 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-83500000 usd
BBLG Estimated Operating Expenditure
EstimatedOperatingExpenditure
5400000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2600000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2800000 usd
CY2024Q3 us-gaap Cash
Cash
3600000 usd
CY2023Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
the Company filed an amendment to its amended and restated certificate of incorporation, as amended, with the Secretary of State of the State of Delaware to effect a 1-for-30 reverse stock split of its outstanding common stock and warrants.
CY2023Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
the Company filed an amendment to its amended and restated certificate of incorporation, as amended, with the Secretary of State of the State of Delaware to effect a 1-for-8 reverse stock split of its outstanding common stock and warrants.
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84B_eus-gaap--UseOfEstimates_zsYi4S8BlJWl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zcoeqMpO1it6">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Significant estimates include the assumptions used in the accrual for potential liabilities, the valuation of the warrant liability, the valuation of debt and equity instruments, the valuation of stock options and warrants issued for services, and deferred tax asset valuation allowances. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q3 BBLG Cash Sipc Insured Amount
CashSIPCInsuredAmount
500000 usd
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
55751 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
38122 usd
CY2024Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
17629 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2020386 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
81198 shares
CY2022Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
54174 shares
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2096740 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
534238 shares
us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
3212504 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
197844 shares
CY2023Q4 BBLG Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
127.86
CY2023 BBLG Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Remaining Contractual Term Beginning
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingContractualTermBeginning
P4Y11M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
3099754 shares
BBLG Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
1.72
BBLG Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Remaining Contractual Term Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingContractualTermGranted
P4Y1M13D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
1443502 shares
BBLG Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
1.30
BBLG Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Remaining Contractual Term Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingContractualTermExercised
P4Y5M4D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
1854096 shares
CY2024Q3 BBLG Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
15.49
BBLG Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Remaining Contractual Term Beginning
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingContractualTermBeginning
P3Y3M14D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
1854096 shares
CY2024Q3 us-gaap Share Price
SharePrice
2.13
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1564895 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
208222 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
34310 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
236.70
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M13D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
137654 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.39
BBLG Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term Granted
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTermGranted
P7Y9M25D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
5674 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
54.24
BBLG Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term Forfeited Expired
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTermForfeitedExpired
P7Y5M15D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
166290 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
48.96
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
36856 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
70139 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
113.57
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P4Y4M6D
CY2024Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
166290 shares
CY2024Q3 us-gaap Share Price
SharePrice
2.13
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
184064 usd
us-gaap Share Based Compensation
ShareBasedCompensation
88065 usd
us-gaap Share Based Compensation
ShareBasedCompensation
81460 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0349 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.4711 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
bblg-20240930_cal.xml Edgar Link unprocessable
0001493152-24-046020-index-headers.html Edgar Link pending
0001493152-24-046020-index.html Edgar Link pending
0001493152-24-046020.txt Edgar Link pending
0001493152-24-046020-xbrl.zip Edgar Link pending
bblg-20240930.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
bblg-20240930_def.xml Edgar Link unprocessable
bblg-20240930_lab.xml Edgar Link unprocessable
bblg-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending